BioCentury
ARTICLE | Tools & Techniques

New framework advocates biomarker-based definition of AD

April 10, 2018 11:25 PM UTC

NIH's National Institute on Aging and the non-profit Alzheimer’s Association released a new framework recommending that Alzheimer's disease research define the disease based on biomarkers rather than solely using clinical symptoms.

The two organizations formed a work group to update a 2011 research framework to incorporate known biomarkers that reflect a continuum of AD progression instead of three distinct symptomatic stages of disease that are commonly used -- preclinical, mild cognitive impairment and dementia. In a review and commentary published in the journal Alzheimer's and Dementia, the work group explained how biomarkers could be used to define AD and how they could be applied to research and clinical trials. ...